위암 치료제 시장 보고서 : 유형별, 투여 경로별, 최종 사용자별, 지역별(2026-2034년)

The global gastric cancer drugs market size reached USD 5.7 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 14.1 Billion by 2034, exhibiting a growth rate (CAGR) of 10.27% during 2026-2034. The expanding geriatric population and the rising incidence of obesity across the world are stimulating the market.

GASTRIC CANCER DRUGS MARKET ANALYSIS:

• Major Market Drivers: The increasing frequency of both acute and chronic indications, the rising weight-related health issues, and the growing awareness about health consciousness are propelling the market.
• Key Market Trends: Rapid technological breakthroughs focused on the development of effective and tailored cancer treatments are contributing to the gastric cancer drugs market growth.
• Competitive Landscape: Some of the major market companies include Abbott Laboratories, Arog Pharmaceuticals Inc., Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, Eli Lilly and Company, F. Hoffmann-La Roche AG, Ono Pharmaceutical Co. Ltd., Sanofi S.A., Taiho Pharmaceutical Co. Ltd. (Otsuka Pharmaceutical Co. Ltd.), among many others.
• Geographical Trends: Asia Pacific is currently dominating the market due to the rising prevalence of gastric cancer, attributed to factors such as poor dietary intake, Helicobacter pylori infections, and an aging population, which is increasing the need for effective treatments.
• Challenges and Opportunities: The high cost of advanced treatments is hampering the market. However, collaborations between governments and pharmaceutical corporations to lower costs and increase affordability will continue to catalyze the market over the forecast period.

GASTRIC CANCER DRUGS MARKET TRENDS:

Rise of Biosimilars

The development of biosimilars for gastric cancer medications is expanding, providing cost-effective alternatives to costly biologics and boosting access to innovative treatments in a variety of countries. In July 2024, Zydus Lifesciences received Mexican regulatory approval to market Mamitra, a trastuzumab biosimilar for breast and gastric cancer treatment, expanding its biosimilar portfolio.

Growth in Advancements in Immunotherapy

The increasing focus on immunotherapy medications, particularly immune checkpoint inhibitors, is driving treatment research for gastric cancer. These medicines boost the immune system's reaction to cancer cells, providing intriguing alternatives to traditional chemotherapy. In October 2024, BeiGene launched the PD-1 cancer drug Tevimbra in the U.S. at a 10% discount to Merck's Keytruda after receiving FDA approval.

Increase in Localized Clinical Trials

A surge in localized clinical trials is driving medication innovation and treatment protocols, with an emphasis on personalizing medicines to specific populations and genetic profiles, thereby boosting the effectiveness and relevance of gastric cancer treatments worldwide. In October 2024, a new study published in the New England Journal of Medicine revealed that gastric cancer patients treated with zolbetuximab, a medicine approved in Europe, had higher survival rates.

GLOBAL GASTRIC CANCER DRUGS INDUSTRY SEGMENTATION:

Breakup by Type:

• Doxorubicin Hydrochloride
• Sunitinib
• Docetaxel
• Mitomycin
• Fluorouracil
• Imatinib
• Trastuzumab

Currently, trastuzumab holds the largest gastric cancer drugs market share

Trastuzumab is a monoclonal antibody that cures HER2-positive gastric cancer by targeting the HER2 protein, which improves patient outcomes and increases survival when combined with chemotherapy.

Breakup by Route of Administration:

• Oral
• Parenteral

Among these, parenteral holds the largest gastric cancer drugs market size

Parenteral administration, such as intravenous infusion, is widely utilized for chemotherapy and targeted therapies, providing quick drug absorption and efficacy in advanced gastric cancer cases.

Breakup by End User:

• Hospitals
• Clinics
• Others

Currently, hospitals dominate the market with the largest gastric cancer drugs market share

Hospitals continue to be important end users, offering modern treatments such as chemotherapy, immunotherapy, and targeted medicines, as well as comprehensive cancer care through specialized oncology departments.

Breakup by Region:

• North America
  • United States
  • Canada
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

Asia Pacific leads in the gastric cancer drugs market growth

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Asia Pacific accounted for the largest gastric cancer drugs market share.

Asia Pacific exhibits a clear dominance in the market driven by government initiatives aimed at improving cancer care and increasing healthcare spending. Furthermore, pharmaceutical corporations are also heavily spending on research and development, resulting in the introduction of new therapies such as targeted treatments and immunotherapy, which are gaining popularity.

COMPETITIVE LANDSCAPE:

The report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market companies have also been provided. Some of the key players in the market include:

• Abbott Laboratories
• Arog Pharmaceuticals Inc.
• Bristol-Myers Squibb Company
• Daiichi Sankyo Company Limited
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• Ono Pharmaceutical Co. Ltd.
• Sanofi S.A.
• Taiho Pharmaceutical Co. Ltd. (Otsuka Pharmaceutical Co. Ltd.)

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Gastric Cancer Drugs Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Type

• 6.1 Doxorubicin Hydrochloride
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Sunitinib
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Docetaxel
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Mitomycin
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Fluorouracil
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast
• 6.6 Imatinib
  • 6.6.1 Market Trends
  • 6.6.2 Market Forecast
• 6.7 Trastuzumab
  • 6.7.1 Market Trends
  • 6.7.2 Market Forecast

7 Market Breakup by Route of Administration

• 7.1 Oral
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Parenteral
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by End User

• 8.1 Hospitals
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Clinics
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Others
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

• 10.1 Overview
• 10.2 Drivers
• 10.3 Restraints
• 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Abbott Laboratories
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
    • 14.3.1.4 SWOT Analysis
  • 14.3.2 Arog Pharmaceuticals Inc.
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
  • 14.3.3 Bristol-Myers Squibb Company
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
    • 14.3.3.4 SWOT Analysis
  • 14.3.4 Daiichi Sankyo Company Limited
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
    • 14.3.4.4 SWOT Analysis
  • 14.3.5 Eli Lilly and company
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT Analysis
  • 14.3.6 F. Hoffmann-La Roche AG
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
  • 14.3.7 Ono Pharmaceutical Co. Ltd.
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 Financials
    • 14.3.7.4 SWOT Analysis
  • 14.3.8 Sanofi S.A.
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
    • 14.3.8.4 SWOT Analysis
  • 14.3.9 Taiho Pharmaceutical Co. Ltd. (Otsuka Pharmaceutical Co. Ltd.)
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 SWOT Analysis